Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal (IP) therapy for patients with gynecologic malignancies.

IP therapy is a treatment with a demonstrated overall survival (OS) benefit, Muggia explains. However, it has not gained enough traction to become a go-to treatment. A recent study published in the Journal of Clinical Oncology showed that IP therapy should be used in ovarian cancer when optimal cytoreduction leads to minimal residual disease.

The published study also reported that there is an OS benefit with IP therapy, with a 25% hazard ratio for reduction of deaths.

View more from the 2015 CFS Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Ovarian Cancer

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

PER® Chemotherapy Foundation Symposium (CFS)

Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal therapy for patients with gynecologic malignancies. 

Dr. Muggia on Current Status of Intraperitoneal Therapy for Gynecologic Cancers